Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biogen, Inc.

https://www.biogen.com

Latest From Biogen, Inc.

ASCO 2023 – Deep And Early Responses Lift Hopes At Effector

New data with a novel RNA translation regulator gave the stock a pre-ASCO boost, but the micro-cap company needs to keep the momentum going.

ASCO Clinical Trials

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

Health policy experts discuss ways Medicare coverage policy may evolve in the coming years and how efforts to smooth the transition between accelerated drug approvals and Medicare reimbursement decisions could play out.

Reimbursement Policy

Medicare Registry Plan For Alzheimer’s Drugs Pairs CMS Web Portal With Health System Efforts

Lack of detail on data elements that would be required through the portal has stakeholders wondering if the Centers for Medicare and Medicaid Services has really found a way to make the registry requirement less of a threat to access for Alzheimer’s drugs with traditional FDA approval.

Reimbursement Policy

Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update

CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry. 

Government Payers Market Access
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Biogen Idec
    • Convergence Pharmaceuticals Ltd
    • Nightstar Therapeutics plc
    • Stromedix, Inc.
    • Syntonix Pharmaceuticals
UsernamePublicRestriction

Register